KRAS G12C Combination Therapy to Overcome Cancer Drug Resistance
Solution Overview
Problem
Current treatments for cancers with KRAS G12C mutations are inadequate, and there is a need for more effective therapeutic means to target this specific mutation.
Innovation Solution
A combination therapy involving KRAS G12C inhibitors, such as AMG-510 or MRTX849, in combination with FAK inhibitors like defactinib, MEK inhibitors like CH5126766, or dual RAF/MEK inhibitors, to treat cancers with KRAS G12C mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single agent is used to treat abnormal cell growth, then the treatment is simple, but the agent must be used at high dosage to overcome resistance, causing increased toxicity to normal cells
Solution Approach 1:
The patent divides the treatment into multiple components by using a combination of two or more agents instead of a single agent. Each agent targets different aspects of abnormal cell growth or different resistance mechanisms, thereby maintaining effectiveness while reducing the need for high dosages of any single agent, thus lowering toxicity to normal cells.
Solution Approach 2:
The patent employs a composite therapeutic approach by combining multiple agents with different mechanisms of action. This composite strategy allows the treatment to address both the abnormal cell growth and the resistance mechanisms simultaneously, improving reliability while reducing the harmful effects associated with high-dose monotherapy.
2Ease of operation
If a single agent is used to treat abnormal cell growth, then the treatment protocol is simple, but resistance develops quickly requiring frequent changes in treatment
Solution Approach 1:
The patent segments the treatment into multiple agents with different mechanisms of action, making it more difficult for abnormal cells to develop resistance to all agents simultaneously. This segmented approach maintains treatment durability while keeping the protocol manageable through established administration procedures for each agent.
Solution Approach 2:
The patent changes the therapeutic parameters by using multiple agents with different mechanisms of action, dosages, and administration schedules. This multi-parameter approach prevents resistance development by ensuring that abnormal cells cannot adapt to all treatment conditions simultaneously, thereby maintaining long-term effectiveness.
3Reliability
If combination therapy is used to treat abnormal cell growth, then resistance is overcome and toxicity is reduced, but the treatment protocol becomes complex
Solution Approach 1:
The patent segments the complex treatment into distinct agent components with specific roles, allowing for systematic management of each agent's administration, dosing, and monitoring. This segmentation makes the complex protocol more manageable by breaking it down into discrete, well-defined elements.
Solution Approach 2:
The patent employs agents with multi-functional properties that can address multiple aspects of abnormal cell growth and resistance mechanisms simultaneously. This universality reduces protocol complexity by using agents that perform multiple functions rather than requiring separate agents for each function.
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3D
AI summary
The present invention relates to methods, compositions, and oral dosage forms of a KRAS G12C inhibitor in combination with a FAK inhibitor and/or a MEK. inhibitor or a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).